P074 | Innovative mrd detection and immune profiling in relapsed cll treated with rituximab-venetoclax: insights from the “dedalus” protocol
Background. Fixed-duration Rituximab (R) and Venetoclax (Ven) therapy has improved outcomes in chronic lymphocytic leukemia (CLL), achieving a 7-year overall survival of 69.6% and effective MRD eradication. Accurate minimal residual disease (MRD) assessment is essential to monitor treatment response...
Zapisane w:
| 1. autor: | |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Ferrata Storti Foundation
2026-03-01
|
| Seria: | Haematologica |
| Dostęp online: | https://haematologica.org/article/view/13333 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|